Polaris Capital Management LLC Has $2.01 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Polaris Capital Management LLC boosted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 29.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,300 shares of the company’s stock after acquiring an additional 13,300 shares during the quarter. Polaris Capital Management LLC owned 0.10% of Harmony Biosciences worth $2,006,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after acquiring an additional 436 shares in the last quarter. Mendota Financial Group LLC raised its stake in shares of Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock valued at $33,000 after acquiring an additional 965 shares during the last quarter. CWM LLC grew its position in Harmony Biosciences by 111.7% during the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after acquiring an additional 775 shares during the last quarter. KBC Group NV raised its position in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock valued at $63,000 after purchasing an additional 819 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in Harmony Biosciences in the third quarter worth $74,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on HRMY. HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Harmony Biosciences in a research report on Monday, January 27th. Oppenheimer reissued an “outperform” rating and issued a $59.00 price target (up previously from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a report on Monday, January 13th. Finally, Cantor Fitzgerald raised their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $55.00.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $37.99 on Tuesday. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The company’s fifty day simple moving average is $35.77 and its 200-day simple moving average is $35.50. The firm has a market cap of $2.17 billion, a PE ratio of 18.00, a P/E/G ratio of 0.51 and a beta of 0.80. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28.

Insider Transactions at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 1,123 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total transaction of $44,920.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Sandip Kapadia sold 1,775 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $38.05, for a total transaction of $67,538.75. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock worth $2,831,679 in the last three months. Insiders own 30.80% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.